Simple test may predict who can handle tough cancer therapy
NCT ID NCT07309497
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a quick, practical geriatric assessment—looking at mobility, memory, self-care, and nutrition—can predict severe side effects in patients 65 and older who are about to receive CAR-T cell or bispecific antibody therapy for blood cancers like multiple myeloma or lymphoma. The goal is to help doctors and patients make more informed decisions and improve quality of life. The study will follow 208 participants and track toxicity, hospital stays, and functional changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a standard pre-treatment check that helps doctors better predict risks and improve quality of life for older patients.
What could go wrong
This is an observational study, not a treatment trial. It may not find a clear link between the assessment and outcomes, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inselspital Bern
RECRUITINGBern, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Zürich
RECRUITINGZurich, 8091, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact